Nektar Therapeutics Announces $250M Equity Offering to Fund Phase 3 Development

summarizeSummary

Nektar Therapeutics plans a $250 million equity offering of common stock and pre-funded warrants, strategically timed with positive Phase 2b clinical trial results for rezpegaldesleukin, to fund its advancement into Phase 3 development.

check_boxKey Events

• Announces Intent for $250 Million Equity Offering

  Nektar Therapeutics filed a preliminary prospectus supplement for a public offering of $250 million in common stock and pre-funded warrants.

• Includes Common Stock and Pre-Funded Warrants

  The offering will consist of shares of common stock and pre-funded warrants, with an exercise price of $0.0001 per warrant.

• Proceeds to Fund Phase 3 Trials for Rezpegaldesleukin

  The net proceeds are intended for general corporate purposes, including research and development, clinical development (specifically Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing costs.

• Strategically Timed with Positive Phase 2b Clinical Data

  This offering follows the company's concurrent announcement of positive 52-week Phase 2b results for rezpegaldesleukin in severe alopecia areata, leveraging favorable market sentiment.

auto_awesomeAnalysis

This preliminary prospectus supplement announces Nektar Therapeutics' intent to raise $250 million through an offering of common stock and pre-funded warrants. The offering is strategically timed, following the company's announcement of positive Phase 2b clinical trial results for rezpegaldesleukin on the same day. Proceeds are earmarked for general corporate purposes, including advancing rezpegaldesleukin into Phase 3 trials for atopic dermatitis and alopecia areata, and covering manufacturing costs. This capital raise is substantial, representing approximately 8.7% of the company's market capitalization, and aims to strengthen the balance sheet and fund critical pipeline development, capitalizing on recent positive clinical momentum. The offering price has not yet been determined, but the last reported sale price on April 17, 2026, was $84.86 per share.